In Brief: CBER
Executive Summary
CBER: Office of Communication, Training and Manufacturers Assistant Director Mark Elengold will serve a 120-day detail as acting deputy director of the center beginning Feb. 16. The biologics center position has been vacant since Michael Beatrice left for contract research and consulting firm BRI in the spring of 1996 ("The Pink Sheet" Feb. 19, 1996 T&G-10). CBER is still interviewing for a replacement...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth